Shenzhen Kangtai Biological Products will produce the possible COVID-19 vaccine from AstraZeneca Plc in mainland China, announced on Thursday the British pharmaceutical company, its first agreement to supply one of the most populous countries in the world. To meet the demand of the Chinese market, Shenzhen Kangtai will have an annual production capacity of at least one hundred million doses of the experimental AZD1222, which AstraZeneca co-developed with researchers at Oxford University, until the end of this year, AstraZeneca said.
Read more: Coronavirus: UAE hosts the world’s first CLINICAL Trials III of the COVID-19 vaccine
You will need to have the ability to produce at least two hundred million doses until the end of next year under the exclusive framework agreement, added on the Chinese social networking site WeChat. The two corporations will also explore the option of cooperation on the candidate vaccine in other markets, AstraZeneca said.